logo
Plus   Neg
Share
Email

FDA's Nicotine Rule Likely To Cost Tobacco Industry $165 Bln: Morgan Stanley

tobacco fda 061819 lt

The U.S. Food and Drug Administration's adoption of a maximum nicotine rule would be a "potential game changer" for the U.S. tobacco industry, but it could also cut profits for major tobacco companies in the U.S. by half, according to Morgan Stanley analysts.

In October, the FDA will publish its proposed rule that regulates the amount of nicotine allowed in cigarettes and other tobacco products.

Under the rule, the agency intends to lower nicotine levels in cigarettes to a minimal or non-addictive level by creating a potential nicotine product standard.

The potential nicotine standard could decrease the chances that future generations become addicted to cigarettes and could also make it easier for more currently addicted smokers to quit, according to the FDA.

In a research report, Morgan Stanley analysts noted that if the regulation is adopted by 2035, it would cost the industry almost $165 billion in lost profits.

However, the reduction of nicotine in cigarettes to non-addictive or minimally addictive levels would also be a potential game changer for the U.S. industry, they said.

Accordingly, the analysts rated the stock of Marlboro-maker Altria Group Inc. and Imperial Brands as underweight, while downgrading British American Tobacco to underweight.

Major tobacco companies in the U.S. are already grappling with dwindling sales of cigarettes amid rising competition and changing consumer habits. Many U.S. citizens have started ditching tobacco due to its health issues.

However, the analysts noted that while tobacco companies will be badly impacted if the policy takes effect by 2035, e-cigarette makers like Juul will benefit due to the consumers' transition from smoking to vaping.

According to the analysts, Altria will be the most at risk if the FDA enacts the maximum nicotine policy.

However, Altria's 35 percent stake in Juul and its agreement with Philip Morris to sell PMI's heated tobacco product in the U.S. makes the company the best placed to transition to alternative nicotine products, they said.

British American Tobacco, which holds only a 10 percent stake of the e-cigarette market, "has a difficult path forward in the U.S.," the analysts noted.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>